Peroxisome proliferator-activated receptor gamma (PPARγ) as a novel target for prostate cancer
Peroxisome proliferator-activated receptor gamma (PPARγ) as a novel target for prostate cancer
复制标题
DOI：
10.1023/a:1015670126203
复制
发表时间：
2002-05-01
影响因子：
3.4
通讯作者：
Kantoff, PW
中科院分区：
文献类型：
--
作者：
Smith, MR;Kantoff, PW
过氧化物酶体增殖物激活受体-γ(PPARGamma)是配体激活的转录因子核受体超家族成员之一。PPARGamma在脂肪组织中高水平表达，在脂肪细胞分化中起核心作用。最近的研究表明，PPARGamma与几种人类恶性肿瘤的发病机制有关。在这里，我们回顾了PPARGamma促进前列腺癌发生的证据，以及PPARGamma作为前列腺癌新的治疗靶点的可能性。
Peroxisome proliferator activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARgamma is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation. Recent studies have implicated PPARgamma in the pathogenesis of several human malignancies. Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer.